Alkeus Pharmaceuticals, Inc. Market Research Report

Company Overview

Name and Mission

Name: Alkeus Pharmaceuticals, Inc.

Mission: To transform the treatment of Stargardt disease and open new possibilities for treating a wide range of patients with degenerative eye diseases.

Founding Information

Founded: 2010

Founders: Leonide Saad, Ph.D., and Ilyas Washington, Ph.D.

Key People

Michel Dahan: President and Chief Executive Officer

Tamara Dillon: Chief Human Resources Officer

Seemi Khan, M.D., M.P.H., M.B.A.: Chief Medical Officer

Leonide Saad, Ph.D.: Co-Founder and Chief Scientific Officer

David Setboun, Pharm.D., M.B.A.: Chief Operating Officer

Eric L. Trachtenberg, J.D., M.B.A.: Chief Legal Officer

Ilyas Washington, Ph.D.: Co-Founder

Headquarters

Location: Cambridge, MA

Number of Employees

No information is available.

Revenue

No information is available.

Company Recognition

Known For: Developing pioneering treatments for degenerative eye diseases, particularly Stargardt disease.

Products

Gildeuretinol (ALK-001)

Description: A once-a-day oral, investigational therapy for the treatment of Stargardt disease. Gildeuretinol is a chemically-modified vitamin A designed to perform all of the functions of vitamin A needed to support sight, but without the tendency to form toxic dimers that damage the retina.

Key Features:

Mechanism of Action: Reduces the rate of vitamin A dimerization in the eye by replacing three hydrogen atoms with deuterium atoms.

Clinical Efficacy: Demonstrated a significant reduction in vitamin A dimer formation by up to 80% in animal models and slowed the growth rate of atrophic lesions in human clinical trials.

Safety Profile: Well-tolerated with a safety profile consistent with vitamin A.

Recent Developments

Recent Achievements

2022: Presentation of Phase 2 results showing that gildeuretinol significantly slows the growth rate of atrophic lesions in patients with advanced Stargardt disease.

New Product Launches

Gildeuretinol (ALK-001): Currently in late-stage development, preparing for potential launch post-approval from regulatory authorities.

New Features and Clinical Trials

TEASE-3 Study: Recent interim data demonstrates that gildeuretinol halts disease progression in early-stage Stargardt disease patients.

Ongoing Clinical Trials:

TEASE-1: A double-masked, placebo-controlled trial showing 21% reduction in retinal atrophic lesion growth.

TEASE-2: An ongoing, fully enrolled trial.

TEASE-3: Open-label study in early-stage patients showing no disease progression.

TEASE-4: Open-label extension study.

New Partnerships and Appointments

July 18, 2024: Presentation of TEASE-3 study update at the 42nd ASRS Annual Scientific Meeting.

July 16, 2024: Appointment of Tamara Dillon as Chief Human Resources Officer.

July 2, 2024: Appointment of Michel Dahan as President and Chief Executive Officer and reappointment of Co-Founder Leonide Saad as Chief Scientific Officer.

May 29, 2024: Appointment of Eric L. Trachtenberg as Chief Legal Officer.

Strategic Advancements

$150 million Series B Funding: Secured in 2023 to support the progression of gildeuretinol (ALK-001).

Regulatory Designations: Received Breakthrough Therapy and Orphan Drug Designations from the U.S. FDA for gildeuretinol.

Contact Information

General Email: [info@alkeuspharma.com](mailto:info@alkeuspharma.com)

Media Relations Email: [media@alkeuspharma.com](mailto:media@alkeuspharma.com)

Expanded Access Requests Email: [expandedaccess@alkeuspharma.com](mailto:expandedaccess@alkeuspharma.com)

Social Media

LinkedIn: [Alkeus Pharmaceuticals](https://www.linkedin.com/AlkeusPharmaceuticals)

Twitter: [@AlkeusPharma](https://www.twitter.com/AlkeusPharma)

Address

Headquarters: Cambridge, MA